{"product_id":"divislabs-pestle-analysis","title":"Divi's Laboratories PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Strategic Decisions with a Complete PESTEL View\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGain a competitive edge with our concise PESTLE Analysis of Divi's Laboratories—uncover how regulatory shifts, economic trends, and technological advances will shape the company’s trajectory and your investment thesis; purchase the full report to access the complete, actionable breakdown and download instantly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical supply chain shifts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGeopolitical China Plus One shifts have driven major pharma buyers to India, boosting Divi's Laboratories; the company’s FY2025 API sales rose ~18% YoY, with exports to regulated markets accounting for ~72% of revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrade policies and export incentives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGovernment schemes like India’s Production Linked Incentive, which allocated about INR 3,000 crore for pharmaceuticals through 2025, bolster competitiveness for API makers and benefit Divi’s by supporting scale and CAPEX; shifts in export duties or trade pacts with the US and EU—markets accounting for an estimated 40–50% of Divi’s export revenue—can materially affect margins; Divi’s actively monitors tariff, origin-rule and subsidy changes to protect its position as a top exporter of high-value intermediates and APIs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal drug pricing regulations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical pressure in the US and EU to curb drug spending has driven policy moves like the US Inflation Reduction Act provisions targeting Medicare drug prices and EU member discussions on external reference pricing, putting downward pressure on finished-dose prices; in 2024 generics price erosion averaged 8–12% in key markets. Although Divi's is B2B, such caps compress API supplier margins; the firm offsets this by prioritizing high-volume generics and complex custom synthesis—segments that accounted for over 60% of 2024 revenue and delivered higher EBITDA per kg, enhancing pricing resilience.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory alignment with international bodies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDiplomatic ties between India and regulators like USFDA and EMA are vital for Divi's export channels; India had 1,180 USFDA inspections through 2024 and exported pharmaceuticals worth $26.5bn in FY2023–24, highlighting the stakes.\u003c\/p\u003e\n\u003cp\u003ePolitical stability and regulatory alignment with ICH standards keep Divi's manufacturing compliant—Divi's FY2024 revenue was ₹3,765 crore, reliant on continuous approvals and inspections.\u003c\/p\u003e\n\u003cp\u003eAny diplomatic friction delaying cross-border inspections risks shipment timelines and contract penalties, potentially affecting margins and client trust.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUSFDA inspections: 1,180 India-wide through 2024\u003c\/li\u003e\n\u003cli\u003eIndia pharma exports: $26.5bn FY2023–24\u003c\/li\u003e\n\u003cli\u003eDivi's FY2024 revenue: ₹3,765 crore\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNational self-reliance initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe Indian government's Atmanirbhar Bharat push boosts domestic manufacture of key starting materials; imports of generic APIs fell 7% YoY in 2024 while domestic capacity investments rose—Divi's aligned capex of ~INR 2,200 crore in FY24–25 targets backward integration to reduce import exposure.\u003c\/p\u003e\n\u003cp\u003eThis political support enables Divi's to secure supply chains, invest in domestic infrastructure, and pursue long-term projects to mitigate external shocks.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAligned capex ~INR 2,200 crore FY24–25\u003c\/li\u003e\n\u003cli\u003eImport reduction trend: −7% YoY (2024)\u003c\/li\u003e\n\u003cli\u003eFocus: backward integration for critical chemicals\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDivi's export-led surge: FY24 ₹3,765cr, FY25 API +18%, PLI \u0026amp; capex bolster resilience\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical dynamics — China Plus One, PLI support (~INR 3,000 crore), US\/EU pricing pressures (generics −8–12% in 2024), and USFDA\/EMA ties — materially shape Divi's export-led FY2024 revenue of ₹3,765 crore and FY2025 API growth ~18% YoY; aligned capex ~INR 2,200 crore and import reduction (−7% YoY) improve resilience.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 revenue\u003c\/td\u003e\n\u003ctd\u003e₹3,765 crore\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2025 API growth\u003c\/td\u003e\n\u003ctd\u003e~18% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExports to regulated markets\u003c\/td\u003e\n\u003ctd\u003e~72% rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePLI for pharma\u003c\/td\u003e\n\u003ctd\u003e~INR 3,000 crore\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex FY24–25\u003c\/td\u003e\n\u003ctd\u003e~INR 2,200 crore\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndia pharma exports FY23–24\u003c\/td\u003e\n\u003ctd\u003e$26.5bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect Divi's Laboratories across six dimensions—Political, Economic, Social, Technological, Environmental, and Legal—backed by current data and trends to highlight threats, opportunities, and forward-looking implications for strategy, funding, and operations in its regional pharma market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise, visually segmented PESTLE summary for Divi's Laboratories that’s easily dropped into presentations or shared across teams to streamline risk discussions and strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency exchange rate volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs an exporter generating over 70% of revenue in FY2024–25, Divi's Laboratories is highly exposed to INR\/USD and INR\/EUR swings; the rupee moved about 4.8% against the dollar in 2025 YTD to December, amplifying translation risk for earnings. Global monetary-policy shifts in 2024–25 drove heightened FX volatility, with USD\/INR 30-day realized volatility averaging ~7% by end-2025. Divi's reports using forward contracts and options—hedging ~60–80% of expected FX flows—to stabilize reported profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal inflation and raw material costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePersistent inflation through 2024–25 raised energy, specialty chemicals and logistics costs by roughly 6–9% year-on-year, pressuring Divi's gross margins despite its scale-based negotiation power with suppliers.\u003c\/p\u003e\n\u003cp\u003eLarge spikes in commodity prices—evident in 2024 when key inputs rose over 15% in peak months—can still compress margins beyond the benefit of volume discounts.\u003c\/p\u003e\n\u003cp\u003eDivi's targets process-chemistry gains and yield improvements, supporting a 2–4% annual reduction in per-unit input intensity observed in 2023–24 to partially offset rising production costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest rate environment and capital expenditure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigher global interest rates raise borrowing costs and can delay Divi’s large-scale capacity expansions—projects often costing hundreds of millions USD—though the company’s net cash position of about $600m at end-FY2025 and low net debt buffer this impact.\u003c\/p\u003e\n\u003cp\u003eRate hikes compress net present value of future projects, reducing valuations; a 100bp rise can materially lower IRR thresholds for new manufacturing blocks.\u003c\/p\u003e\n\u003cp\u003eDivi times strategic investments to coincide with global API demand cycles and favorable financing; recent capex guidance of $200–250m for 2024–25 reflects this calibrated approach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEconomic growth in emerging markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRising healthcare spending in emerging markets—projected to grow at ~6.1% CAGR in Asia Pacific and 5.0% in Africa through 2025—expands demand for generics and APIs, benefiting Divi's Laboratories' cost-efficient manufacturing footprint.\u003c\/p\u003e\n\u003cp\u003eDivi's can capture share as countries like India and Nigeria increase public health budgets and advance universal healthcare, supporting sustained volume growth in API and generic supply chains.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEmerging market healthcare spend growth: Asia Pacific ~6.1% CAGR to 2025, Africa ~5.0%\u003c\/li\u003e\n\u003cli\u003eDivi's competitive edge: low-cost manufacturing and scale in API production\u003c\/li\u003e\n\u003cli\u003eUniversal healthcare rollouts in Asia\/Africa act as multi-year volume drivers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR and D investment trends in Big Pharma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe economic health of global innovator pharma firms drives demand for Divi's custom synthesis; global Big Pharma R\u0026amp;D spending reached about $210 billion in 2024, up ~3% year-on-year, supporting higher outsourcing to CMOs like Divi's.\u003c\/p\u003e\n\u003cp\u003eWhen R\u0026amp;D budgets rise, Divi's sees greater contract volumes; conversely, 2024 patent cliffs and occasional downturn-linked budget cuts cause volatility in manufacturing orders and pricing pressure.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal Big Pharma R\u0026amp;D ~ $210B (2024)\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D growth ~ +3% YoY (2024)\u003c\/li\u003e\n\u003cli\u003ePatent cliffs\/downturns = higher demand volatility for CMOs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDivi’s export tilt and FX exposure amid rising costs, $600m cash and $200–250m capex\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExport-reliant (70%+ revenue FY2025) exposes Divi's to FX swings; USD\/INR volatility ~7% (end-2025); hedging covers ~60–80% of flows. Inflation (2024–25) raised input\/logistics costs ~6–9%; commodities spiked \u0026gt;15% in 2024. Net cash ~$600m (end-FY2025) and capex guidance $200–250m for 2024–25. Global Big Pharma R\u0026amp;D ~$210bn (2024), +3% YoY, supporting CMO demand.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eExports (% rev)\u003c\/td\u003e\n\u003ctd\u003e70%+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUSD\/INR vol\u003c\/td\u003e\n\u003ctd\u003e~7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHedging\u003c\/td\u003e\n\u003ctd\u003e60–80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInput cost rise\u003c\/td\u003e\n\u003ctd\u003e6–9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet cash\u003c\/td\u003e\n\u003ctd\u003e$600m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex\u003c\/td\u003e\n\u003ctd\u003e$200–250m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBig Pharma R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$210bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eDivi's Laboratories PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Divi's Laboratories PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategic planning and investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751467725177,"sku":"divislabs-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/divislabs-pestle-analysis.png?v=1772231795","url":"https:\/\/growthsharematrix.com\/products\/divislabs-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}